Table 4 Multivariate analysis of factors influencing the treatment efficacy of first-line EGFR-TKIs.
Variables | HR | 95% CI | P value |
|---|---|---|---|
(a) Multivariate analysis of factors influencing PFS with first-line EGFR-TKIs | |||
Minocycline over 30 days | 0.44 | 0.27–0.73 | 0.0014 |
Age > 75 | 0.89 | 0.56–1.44 | 0.64 |
Male | 0.76 | 0.36–1.58 | 0.46 |
Smoking | 1.60 | 0.77–3.36 | 0.21 |
EGFR minor mutation | 0.81 | 0.41–1.62 | 0.56 |
Osimertinib | 0.49 | 0.26–0.92 | 0.027 |
Recurrence after surgery | 0.49 | 0.26–0.92 | 0.0010 |
Skin rash | 0.86 | 0.54–1.35 | 0.51 |
Hepatic dysfunction | 1.28 | 0.74–2.19 | 0.38 |
Gastrointestinal toxicity | 1.25 | 0.76–2.06 | 0.38 |
(b) Multivariate analysis of factors influencing OS with first-line EGFR-TKIs | |||
Minocycline over 30 days | 0.50 | 0.27–0.92 | 0.027 |
Age > 75 | 1.27 | 0.72–2.25 | 0.41 |
Male | 0.55 | 0.23–1.30 | 0.17 |
Smoking | 2.14 | 0.92–4.99 | 0.078 |
EGFR minor mutation | 0.88 | 0.37–2.10 | 0.78 |
Osimertinib | 0.38 | 0.13–1.12 | 0.079 |
Recurrence after surgery | 0.48 | 0.27–0.83 | 0.0085 |
Skin rash | 0.73 | 0.40–1.33 | 0.30 |
Hepatic dysfunction | 0.74 | 0.38–1.44 | 0.37 |
Gastrointestinal toxicity | 1.66 | 0.91–3.03 | 0.098 |
